Cargando…

The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model

The cellular and molecular mechanisms via which MK2206, an AKT inhibitor, prevents the activation of AKT in toluene diisocyanate (TDI)-induced asthma remain unclear. Thus, the present study aimed to evaluate the potential effects of MK2206 on airway AKT activation, inflammation and remodeling in a T...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Haiyan, Cheng, Yuanxiong, He, Yi, Cheng, Weiying, Zhao, Wenqu, Zhao, Haijin, Zhou, Fiona H., Wang, Liping, Dong, Jianghui, Cai, Shaoxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533517/
https://www.ncbi.nlm.nih.gov/pubmed/33000187
http://dx.doi.org/10.3892/mmr.2020.11450
_version_ 1783590151927103488
author Cui, Haiyan
Cheng, Yuanxiong
He, Yi
Cheng, Weiying
Zhao, Wenqu
Zhao, Haijin
Zhou, Fiona H.
Wang, Liping
Dong, Jianghui
Cai, Shaoxi
author_facet Cui, Haiyan
Cheng, Yuanxiong
He, Yi
Cheng, Weiying
Zhao, Wenqu
Zhao, Haijin
Zhou, Fiona H.
Wang, Liping
Dong, Jianghui
Cai, Shaoxi
author_sort Cui, Haiyan
collection PubMed
description The cellular and molecular mechanisms via which MK2206, an AKT inhibitor, prevents the activation of AKT in toluene diisocyanate (TDI)-induced asthma remain unclear. Thus, the present study aimed to evaluate the potential effects of MK2206 on airway AKT activation, inflammation and remodeling in a TDI-induced mouse model of asthma. A total of 24 BALB/c mice were selected and randomly divided into untreated (AOO), asthma (TDI), MK2206 (TDI + MK2206), and dexamethasone (TDI + DEX) groups. Phosphorylated AKT (p-AKT), total AKT, airway remodeling indices, α-smooth muscle actin (α-SMA) and collagen I levels in pulmonary tissue were measured using western blotting. Airway inflammation factors, including interleukin (IL)-4, −5, −6, and −13 in bronchoalveolar lavage fluid (BALF) and IgE in serum, were determined using ELISA. Additionally, the airway hyperresponsiveness (AHR) and pulmonary pathology of all groups were evaluated. The results of the present study demonstrated that p-AKT levels in lung protein lysate were upregulated, and neutrophil, eosinophil and lymphocyte counts were increased in the lungs obtained from the asthma group compared with the AOO group. Both MK2206 and DEX treatment in TDI-induced mice resulted not only in the attenuation of AKT phosphorylation, but also reductions in neutrophil, eosinophil and lymphocyte counts in the lungs of mice in the asthma group. Consistently, increases in the levels of the inflammatory cytokines IL-4, −5, −6 and −13 analyzed in BALF, and serum IgE in the TDI group were demonstrated to be attenuated in the TDI + MK2206 and TDI + DEX groups. Furthermore, α-SMA and AHR were significantly attenuated in the TDI + MK2206 group compared with the TDI group. These results revealed that MK2206 not only inhibited AKT activation, but also served a role in downregulating airway inflammation and airway remodeling in chemical-induced asthma. Therefore, the findings of the present study may provide important insight into further combination therapy.
format Online
Article
Text
id pubmed-7533517
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-75335172020-10-07 The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model Cui, Haiyan Cheng, Yuanxiong He, Yi Cheng, Weiying Zhao, Wenqu Zhao, Haijin Zhou, Fiona H. Wang, Liping Dong, Jianghui Cai, Shaoxi Mol Med Rep Articles The cellular and molecular mechanisms via which MK2206, an AKT inhibitor, prevents the activation of AKT in toluene diisocyanate (TDI)-induced asthma remain unclear. Thus, the present study aimed to evaluate the potential effects of MK2206 on airway AKT activation, inflammation and remodeling in a TDI-induced mouse model of asthma. A total of 24 BALB/c mice were selected and randomly divided into untreated (AOO), asthma (TDI), MK2206 (TDI + MK2206), and dexamethasone (TDI + DEX) groups. Phosphorylated AKT (p-AKT), total AKT, airway remodeling indices, α-smooth muscle actin (α-SMA) and collagen I levels in pulmonary tissue were measured using western blotting. Airway inflammation factors, including interleukin (IL)-4, −5, −6, and −13 in bronchoalveolar lavage fluid (BALF) and IgE in serum, were determined using ELISA. Additionally, the airway hyperresponsiveness (AHR) and pulmonary pathology of all groups were evaluated. The results of the present study demonstrated that p-AKT levels in lung protein lysate were upregulated, and neutrophil, eosinophil and lymphocyte counts were increased in the lungs obtained from the asthma group compared with the AOO group. Both MK2206 and DEX treatment in TDI-induced mice resulted not only in the attenuation of AKT phosphorylation, but also reductions in neutrophil, eosinophil and lymphocyte counts in the lungs of mice in the asthma group. Consistently, increases in the levels of the inflammatory cytokines IL-4, −5, −6 and −13 analyzed in BALF, and serum IgE in the TDI group were demonstrated to be attenuated in the TDI + MK2206 and TDI + DEX groups. Furthermore, α-SMA and AHR were significantly attenuated in the TDI + MK2206 group compared with the TDI group. These results revealed that MK2206 not only inhibited AKT activation, but also served a role in downregulating airway inflammation and airway remodeling in chemical-induced asthma. Therefore, the findings of the present study may provide important insight into further combination therapy. D.A. Spandidos 2020-11 2020-08-21 /pmc/articles/PMC7533517/ /pubmed/33000187 http://dx.doi.org/10.3892/mmr.2020.11450 Text en Copyright: © Cui et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Cui, Haiyan
Cheng, Yuanxiong
He, Yi
Cheng, Weiying
Zhao, Wenqu
Zhao, Haijin
Zhou, Fiona H.
Wang, Liping
Dong, Jianghui
Cai, Shaoxi
The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title_full The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title_fullStr The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title_full_unstemmed The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title_short The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
title_sort akt inhibitor mk2206 suppresses airway inflammation and the pro-remodeling pathway in a tdi-induced asthma mouse model
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533517/
https://www.ncbi.nlm.nih.gov/pubmed/33000187
http://dx.doi.org/10.3892/mmr.2020.11450
work_keys_str_mv AT cuihaiyan theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT chengyuanxiong theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT heyi theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT chengweiying theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhaowenqu theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhaohaijin theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhoufionah theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT wangliping theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT dongjianghui theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT caishaoxi theaktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT cuihaiyan aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT chengyuanxiong aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT heyi aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT chengweiying aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhaowenqu aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhaohaijin aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT zhoufionah aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT wangliping aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT dongjianghui aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel
AT caishaoxi aktinhibitormk2206suppressesairwayinflammationandtheproremodelingpathwayinatdiinducedasthmamousemodel